Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on September 19, 2005

Hypertension. 2005
Published online before print September 19, 2005, doi: 10.1161/01.HYP.0000184250.37607.da
A more recent version of this article appeared on October 1, 2005
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
46/4/772    most recent
01.HYP.0000184250.37607.dav1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chade, A. R.
Right arrow Articles by Lerman, L. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chade, A. R.
Right arrow Articles by Lerman, L. O.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Cholesterol
Related Collections
Right arrow Animal models of human disease
Right arrow Pathophysiology

Submitted on March 25, 2005
Revised on April 18, 2005

Pathways of Renal Fibrosis and Modulation of Matrix Turnover in Experimental Hypercholesterolemia

Alejandro R. Chade; Oren P. Mushin; Xiangyang Zhu; Martin Rodriguez-Porcel; Joseph P. Grande; Stephen C. Textor; Amir Lerman*; and Lilach O. Lerman

From the Department of Internal Medicine, Divisions of Nephrology and Hypertension (A.R.C., O.P.M., X.Z., S.C.T., L.O.L.) and Cardiovascular Diseases (M.R.-P., A.L., L.O.L.), and Laboratory Medicine and Pathology (J.P.G.), Mayo Clinic College of Medicine, Rochester, Minn.

* To whom correspondence should be addressed. E-mail: lerman.lilach{at}mayo.edu.

Abstract--Dyslipidemia often accompanies and accelerates renal disease, partly by promoting fibrosis. However, the mechanisms mediating this effect are unclear. We hypothesized that hypercholesterolemia modulates several interlinked pathways that promote deposition and blunt degradation of extracellular matrix, and that these could be manipulated by reversal of hypercholesterolemia. Fourteen pigs were fed a 16-week 2% high-cholesterol diet (HC-HC; n=7) or normal diet (n=7), whereas in 7 others, a 10-week HC was followed by a 6-week normal diet (HC-N). Renal endothelial function was assessed in vivo with electron-beam computed tomography, and renal tissue was then studied ex vivo using Western blot, real-time quantitative polymerase chain reaction, gelatin zymography, and immunostaining. HC-HC kidneys showed endothelial dysfunction, accompanied by increased intrarenal oxidative stress, inflammation, activation of the endothelin and transforming-growth factor-{beta} systems, and decreased matrix metalloproteinase expression and activity. Accordingly, HC-HC kidneys showed increased collagen IV expression and fibrosis. A lipid-lowering dietary intervention reversed most of these changes. In conclusion, this study indicates that renal fibrosis in early atherosclerosis is a result of a simultaneous increase in extracellular matrix deposition and blunted matrix metalloproteinase-mediated degradation, overall promoting perivascular and tubulointerstitial fibrosis. Notably, many of these pathways may be reversible in hypercholesterolemia, and crucial targets could potentially be identified for early interventions to preserve the kidney.


Key words: kidney • hypercholesterolemia • fibrosis • remodeling • oxidative stress




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
P. Boor, K. Sebekova, T. Ostendorf, and J. Floege
Treatment targets in renal fibrosis
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407.
[Full Text] [PDF]


Home page
Circ. Res.Home page
J. Herrmann, A. M. Saguner, D. Versari, T. E. Peterson, A. Chade, M. Olson, L. O. Lerman, and A. Lerman
Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis
Circ. Res., October 26, 2007; 101(9): 865 - 874.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. R. Chade, J. D. Krier, O. Galili, A. Lerman, and L. O. Lerman
Role of Renal Cortical Neovascularization in Experimental Hypercholesterolemia
Hypertension, October 1, 2007; 50(4): 729 - 736.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. M. Okamura, J. M. Lopez-Guisa, K. Koelsch, S. Collins, and A. A. Eddy
Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury
Am J Physiol Renal Physiol, August 1, 2007; 293(2): F575 - F585.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
X.-Y. Zhu, E. Daghini, A. R. Chade, C. Napoli, E. L. Ritman, A. Lerman, and L. O. Lerman
Simvastatin Prevents Coronary Microvascular Remodeling in Renovascular Hypertensive Pigs
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1209 - 1217.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. R. Chade, J. D. Krier, S. C. Textor, A. Lerman, and L. O. Lerman
Endothelin-A Receptor Blockade Improves Renal Microvascular Architecture and Function in Experimental Hypercholesterolemia
J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3394 - 3403.
[Abstract] [Full Text] [PDF]